Abstract

Lymphomas may often present with more than one pathologic type in the same individual. This study assesses the variability of FDG uptake values as determined by SUV's in various lymphoma subtypes to serve as a platform for differentiating and confirming the pathologic diagnosis in all disease sites.Methods: We retrospectively evaluated the PET-CT studies of 184 lymphoma patients at initial staging or at relapse prior to therapy. Lymphoma subtypes were classified according to the WHO classification. SUV's were obtained in a total of 1120 nodal or extranodal disease sites in 11 lymphoma subtypes. Mean SUV's were calculated for each lymphoma subtype by dividing the total maximum SUV's by the number of disease sites in all patients. Consequently, mean SUV +/− SD and SUV range were determined and correlated with histologic diagnosis as shown in the Table.Results: Results are summarized in Table 1. The highest mean SUV's were obtained in aggressive non-Hodgkin's lymphomas (NHL) followed by Hodgkin's disease (HD) and indolent NHL. Starting from the subtype with the highest mean SUV of the means and in a rank of decreasing order, the subtypes of lymphoma are as follows; Burkitts, DLCL, T cell rich B cell, natural killer T cell, HD, Anaplastic T-cell, mantle cell, marginal zone, follicular, T cell peripheral and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).Conclusions: While SUV's may be quite variable, a general pattern does exist for each lymphoma subtype. A major discrepancy between the SUV's and histologic diagnosis should be assessed by repeat biopsy.SUV Distribution Among Subtypes of Lymphoma*Type of LymphomaPatient NumberMean+/−SDRangeHD457.5+/−3.72–22Mantle cell86.8+/−4.92.1–21DLCL5811.3+/−7.32.2–58T cell Rich B cell59.1+/−5.54–25Burkitts911.8+/−10.52–44Follicular305.1+/−2.71.6–11CLL/SLL113.0+/−1.51.1–8.8Marginal Zone105.5+/−3.82.1–21*Table does not cover all lymphoma subtypes studied in this study due to limited space, HD: Hodgkins Disease NHL: Non Hodgkins lymphoma, DLCL: Diffuse large cell lymphoma, CLL/SLL: Chronic lymphocytic leukemia/small lymphocytic lymphoma

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.